HumaninvsSelank

Humanin is a 24-amino-acid peptide (MAPRGFSCLLLLTSEIDLPVKRRA) encoded within the 16S ribosomal RNA gene of the mitochondrial genome. Its discovery in 2001 was revolutionary — it was the first identified mitochondrial-derived peptide (MDP), challenging the long-held dogma that the mitochondrial genome only encodes 13 oxidative phosphorylation subunits, 22 tRNAs, and 2 rRNAs. Humanin, along with MOTS-C and the SHLP peptides discovered later, established mitochondria as endocrine organelles.

Humanin exerts cytoprotective effects through multiple mechanisms. Extracellularly, it binds to a trimeric receptor complex composed of CNTFR (ciliary neurotrophic factor receptor alpha), WSX-1 (IL-27 receptor alpha), and gp130 (the shared signaling subunit of the IL-6 receptor family). Activation of this complex triggers JAK/STAT3 signaling, which drives expression of anti-apoptotic genes (Bcl-2, Mcl-1) and cell survival programs. Intracellularly, humanin interacts directly with two pro-apoptotic proteins: it binds IGFBP-3, preventing IGFBP-3 from translocating to mitochondria and initiating apoptosis; and it binds BAX (Bcl-2-associated X protein), preventing BAX oligomerization and insertion into the outer mitochondrial membrane — the critical step in the intrinsic (mitochondrial) apoptosis pathway that releases cytochrome c and activates caspases.

Humanin also reduces cellular stress through multiple pathways. It decreases reactive oxygen species (ROS) production by optimizing mitochondrial electron transport chain function. It reduces endoplasmic reticulum (ER) stress by modulating the unfolded protein response (UPR). It improves insulin sensitivity through STAT3-mediated effects on hypothalamic signaling and peripheral insulin receptor substrate phosphorylation. Circulating humanin levels decline with age (approximately 40% reduction between youth and old age) and are inversely correlated with markers of age-related disease, suggesting that humanin decline contributes to the increased cellular vulnerability and apoptosis susceptibility seen in aging. Its most potent synthetic analogue, HNG (S14G-humanin), has a glycine-for-serine substitution at position 14 that increases cytoprotective potency approximately 1,000-fold.

Selank is a synthetic heptapeptide based on the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), with a stabilizing Pro-Gly-Pro extension at the C-terminus that dramatically increases its resistance to aminopeptidase degradation. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it was designed to combine the immune-enhancing effects of tuftsin with anxiolytic and nootropic properties.

The anxiolytic mechanism involves modulation of GABAergic neurotransmission. Selank acts as an allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA in anxiety-related brain regions including the amygdala, hippocampus, and prefrontal cortex. This produces a benzodiazepine-like anxiolytic effect without the sedation, cognitive impairment, or addiction potential associated with benzodiazepines — because Selank modulates rather than directly activates the receptor. Additionally, Selank stabilizes enkephalins (endogenous opioid pentapeptides) by inhibiting enkephalin-degrading enzymes (aminopeptidases and enkephalinase/neprilysin), prolonging their mood-regulating and anxiolytic signaling.

The nootropic effects are mediated through neurotrophic factor upregulation. Selank increases expression of brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex, promoting dendritic branching, synaptic plasticity, and long-term potentiation — the cellular mechanisms underlying memory formation and cognitive flexibility. It also modulates serotonergic (5-HT) metabolism, altering the balance between serotonin and its metabolite 5-HIAA in key brain regions. The immunomodulatory component derives from the tuftsin core: tuftsin naturally activates monocytes and macrophages through specific receptors, enhancing phagocytic activity and modulating IL-6, TNF-α, and other cytokine production. This immune regulation occurs at sub-anxiolytic doses, suggesting it is an independent pharmacological effect. The combined anxiolytic, cognitive-enhancing, and immunomodulatory profile is unique among available peptides.